Osivax, Lyon, France.
ANSES, Laboratory for Rabies and Wildlife, Malzéville, France.
Front Immunol. 2023 Jun 19;14:1188605. doi: 10.3389/fimmu.2023.1188605. eCollection 2023.
Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM, a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.
基于尖峰的 COVID-19 疫苗可诱导出强大的中和抗体，但它们对 SARS-CoV-2 变体的功效降低。OVX033 是一种重组蛋白，由 SARS-CoV-2 的全长核衣壳（N）蛋白与寡聚 DOM 基因融合而成，寡聚 DOM 是一种自我组装结构域，可提高抗原的免疫原性。OVX033 将 N 作为抗原靶标，被提议作为一种新的候选疫苗，可提供针对 sarbecoviruses 的广谱保护。OVX033 在仓鼠攻毒模型中证明了其能够引发交叉反应性 T 细胞反应和对三种 SARS-CoV-2 变体（B.1 欧洲、Delta B.1.617.2 和 Omicron B.1.1.529）的交叉保护作用，这表现在体重减轻较少、肺部病毒载量较低和肺部组织病理学损伤减少。
